The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1346
September 6, 2010
View Complete Issue         Table of Contents 2019 
New Treatments for Metastatic Prostate Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
New Treatments for Metastatic Prostate Cancer
September 6, 2010 (Issue: 1346)
The FDA has approved 2 new treatments for castration-resistant (formerly called hormone-refractory) prostate cancer. Sipuleucel-T (Provenge – Dendreon) is the first immunotherapy approved for treatment of prostate cancer. Cabazitaxel (Jevtana –...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: New Treatments for Metastatic Prostate Cancer
Article code: 1346b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.